#Pharmacy Clinic Saskatchewan Canada | Explore Tumblr posts and blogs

covid-safer-hotties · 1 month ago

Text

Also preserved on our archive

By Hannah Alberga and Nicole Ireland

The federal government’s decision to not provide Novavax’s COVID-19 vaccine this respiratory virus season raises health equity concerns, experts and advocates say, as some Canadians look to the U.S. to get the shot.

The Public Health Agency of Canada said it won’t provide the protein-based vaccine called Nuvaxovid because the manufacturer required a minimum order that far exceeds last year’s uptake of the vaccine.

The health agency said 125,000 Nuvaxovid doses were ordered in 2023, but only 5,529 were administered. This fall, it will only supply provinces and territories with the reformulated Pfizer-BioNTech and Moderna mRNA COVID-19 vaccines.

But some Canadians who say they are immunocompromised and have had adverse reactions to the mRNA vaccines are calling the decision unfair.

Among them is 64-year-old Linda Wilhelm, who has rheumatoid arthritis and takes immunosuppressive drugs for the chronic inflammatory disorder. The Bloomfield-N.B. resident said she received six mRNA COVID-19 vaccines over a three-year period, but her last shot caused a flare-up in her joints that lasted eight months.

Wilhelm said the flare-up was so bad that she even had trouble brushing her hair or chopping vegetables.

After searching for Nuvaxovid at various pharmacies and public health clinics, she said she eventually got a dose in April at a pharmacy in Saint John, N.B., and had no adverse reactions.

“And now, again, I have no options,” Wilhelm said, adding that she’s considering driving across the border to Maine to get the updated Nuvaxovid shot.

Barry Hunt made the cross-border trip last month from Port Ryerse, Ont., to a pharmacy near Buffalo, N.Y., where he paid US$200 to get the Novavax vaccine.

The 61-year-old, who has a lasting joint infection from a knee surgery complication, said he had a six months-long adverse reaction to his fourth mRNA shot that caused tightness in his chest and fatigue.

But he acknowledged that most people seeking Nuvaxovid don’t have the means to travel to the U.S. to get it.

“I think it’s unfair to people who can’t afford it. I think it’s ridiculous to both pay taxes here in Canada for universal health care under the Canada Health Act and not be able to access a non-mRNA vaccine,” Hunt said.

Angela Rasmussen, a virologist at the University of Saskatchewan’s Vaccine and Infectious Disease Organization, said some people may be sensitive to some components of mRNA vaccines but overall they are safe for immunosuppressed people.

“It’s disappointing that Novavax won’t be available here because I think it could increase vaccine uptake just by virtue of overcoming objections to mRNA vaccines, whether based in truth or not,” she said in an email.

Other experts say research also shows that, except in very rare circumstances, it is safe for people taking immunosuppressive drugs to get an mRNA vaccine, even though some patients report flare-ups of their conditions.

Specialists often ask patients with autoimmune diseases to stop taking their medications while they get vaccinated to ensure they can mount a good immune response, and the absence of medication may be what’s actually triggering the flare-ups rather than the mRNA vaccine itself, said Dawn Bowdish, an immunology professor at McMaster University in Hamilton.

Still, Nuvaxovid is “clearly less what we call reactogenic, meaning you’re less likely to feel poorly or have a sore arm or have any of those side-effects that some people … get from vaccines,” said Bowdish, who has worked with immunocompromised people in clinical studies on mRNA vaccines.

Novavax’s vaccine, reformulated to target the recently circulating JN.1 subvariant of Omicron, was authorized by Health Canada in September.

People who have concerns or had a bad immunization experience should have access to Nuvaxovid, Bowdish said, because it’s crucial they get some kind of vaccination against COVID-19, which is especially dangerous for the immunocompromised.

The Public Health Agency of Canada said people worried about getting an mRNA vaccine should consult their health-care provider.

Those who are medically unable to receive an mRNA vaccine should protect themselves by practising hand hygiene, wearing a well-fitting mask and improving indoor ventilation, the agency said.

“That response is absolutely appalling,” said Michelle Burleigh, co-chair of the Canadian Immunocompromised Advocacy Network, which sent a letter to the federal government in July urging it to procure Novavax.

“It’s great if somebody has the financial means and ability to travel to the U.S., but this causes a real health equity issue because there are a lot of Canadians who are not in a position to afford $200 for a vaccine in the United States or have the ability to get there.”

Bowdish said she’s also aware of people travelling to the U.S. to get Nuvaxovid and that’s “really problematic.”

Although the latest data suggest flare-ups of certain conditions are unlikely to be a direct result of the mRNA vaccine, it’s still important to accommodate patients, she said.

“If a person’s personal experience was, ‘I got vaccinated and I had a flare that put me in bed for two months and … I missed a part of life,’ how on earth do you counter that while being respectful over their autonomy and knowing their own bodies?”

This report by The Canadian Press was first published Oct. 3, 2024.

Canadian Press health coverage receives support through a partnership with the Canadian Medical Association. CP is solely responsible for this content.

#mask up #covid #covid 19 #pandemic #wear a mask #public health #coronavirus #still coviding #sars cov 2 #wear a respirator #canada #novavax

7 notes · View notes

isupportonlinedoctor · 2 months ago

Text

Gotodoctor Welcomes Andrew Duckman as Senior Advisor

Gotodoctor.ca is pleased to welcome Andrew Duckman to its organization as Senior Advisor to the CEO office.

Andrew Duckman is a trusted corporate development and investment advisor with an entrepreneurial spirit. Over his 20+ year career, Andrew has worked from the ground up and developed top-tier relationships with some of the most influential investors and companies across the country. Most recently with Fort Capital, Echelon Wealth Partners and Bloom Burton & Co, Andrew’s experience spans several sectors, including healthcare, healthcare technology and financial services, with a focus on providing strategic counsel and guidance to companies whose values align with his own.

“Gotodoctor.ca’s is a one-of-a-kind digital healthcare platform at the forefront of disrupting the primary care delivery market,” said Andrew Duckman. “This opportunity aligns perfectly with my interest in healthcare and I am eager to make a meaningful impact along with the Gotodoctor.ca team’s mission of enhancing access to care for Canadians, while aligning with the public healthcare system.”

“Andrew has a wealth of experience in healthcare, insurance, and capital markets,” said Tommy Cheung, CEO of Gotodoctor.ca. “We look forward to drawing on his expertise and insights to accelerate the growth of Gotodoctor to its next stage.”

About Gotodoctor.ca

Gotodoctor.ca is a leading B2B healthcare technology platform that connects to an estimated a million Canadians through its unique Service Engine and hybrid primary care network. If you are looking for booking doctor appointment in Saskatchewan, then get in touch with Gotodoctor.ca

The platform integrates virtual care and in-person pharmacy and clinic Service Sites, and enables members to access comprehensive and scalable physician and other healthcare services. Gotodoctor.ca is a preferred provider for McKesson Canada’s Rexall and Retail Banner Group (IDA, Guardian, Remedy’s Rx) pharmacies. Its Digital Employee Services and Data Offerings technologies are already adopted and are utilized by major Canadian Enterprises, TPAs, and other enterprises, like Manitoba Blue Cross, Novartis Canada, SEB Administrative Services/Co-Operators, The Leslie Group, Quick Health Access, Simply Beneﬁts, and Automated Administration Services.

#online doctor appointment #medical doctor online saskatchewan #virtual doctor #telehealth saskatchewan

0 notes

aptechvisaglobalimmigration · 3 years ago

Text

Saskatchewan has released a new EOI for international healthcare workers.

A new International Healthcare Worker Expression of Interest (EOI) Pool has been established in Saskatchewan.

The Saskatchewan Immigrant Nominee Program will manage the pool (SINP).

The new International Healthcare Worker EOI submission method is a pre-application form that lets candidates to submit an online form stating their interest in working in a certain health care occupation in Saskatchewan, rather than an application to the SINP.

Saskatchewan will check your qualifications and, if you possess the abilities that an employer seeks, you will be contacted with information on how to apply for a job opening.

You may be eligible for either the SINP International Job Offer or the Hard-to-Fill Skills Pilot if you receive an offer of employment.

A tutorial on how to build an EOI profile may be found on the SINP website. You must have professional training that corresponds to less than one of the following National Occupation Classification (NOC) codes to submit an EOI.

NOC Codes That Are Eligible: EOI Pool for International Healthcare Workers

NOC

Occupation Titles

1252

Health Information Management Practitioner

3012

Registered Nurse and Registered Psychiatric Nurse

3122

Chiropractors

3124

Nurse Practitioner

3131

Pharmacist

3141

Audiologist and Speech Language Pathologist

3142

Physical Therapist

3143

Occupational Therapist

3211

Combined Laboratory & X‐Ray Technologist, Clinical Genetics Technologist, and Medical Laboratory Technologist

3212

Medical laboratory technicians and pathologists’ assistants

3214

Respiratory Therapists, Cardiopulmonary Function Technologist, Per fusionist

3215

Magnetic Resonance Imaging Technologist, Medical Radiation Technologist, Nuclear Medicine Technologist

3216

Diagnostic Cardiac Sonographers, Diagnostic Medical Sonographers

3217

Cardiology Technologist and Cardiovascular Technologist, Electro neurophysiology Technologist

3219

Pharmacy Technician

3223

Dental technologists, technicians and laboratory assistants

3233

Licensed Practical Nurse

3234

Emergency Medical Technician

3237

Other technical occupations in therapy and assessment

3413

Continuing Care Assistant

4151

Psychologist (Masters and PhD)

Job Offer for an International Skilled Worker

This stream's eligibility requirements include:

• Obtain a minimum Canadian Language Benchmark (CLB) score of 4 across all four language competencies if you are already resident in Canada (reading, writing, speaking, and listening)

• Have a permanent full-time offer of employment from a Saskatchewan employer registered under SINP.

• Have a minimum of one year of paid work experience in the anticipated occupation within the past 10 years.

• Provide proof of eligibility for the Saskatchewan license if your offer of employment is for a regulated occupation in Saskatchewan requiring a compulsory licensing.

• On the points assessment grid, get at least 60 points out of a possible 110.

Hard-to-Fill Skills Pilot

The following are the pilot criteria, which were just announced on November 25, 2021:

• Possess a permanent, full-time work offer from a SINP-registered Saskatchewan employer.

• Comply with the CLB's minimal linguistic requirement

· Have at least a year of professional experience in the same occupation as the offer of employment or six months professional experience in the same position in Saskatchewan.

For more info, please Call: +91-7503832132, Write to us at: [email protected] or Fill Free Canada Immigration Assessment Form

#saskatchewan pnp #saskatchewan pnp draw #saskatchewan immigration #Saskatchewan Occupation in-Demand #SINP Occupation List 2021 Updated

0 notes

atlanticcanada · 3 years ago

Text

So you did a rapid COVID-19 test and the results are positive. Now what?

As the new Omicron COVID-19 variant causes case numbers to surge, many Canadians are hoping self-test kits can help keep their families safe over the holidays. Also known as rapid antigen tests, these can easily be done at home and provide results in less than 20 minutes.

Taken soon before a gathering, experts say the tests can supply an added layer of confidence and protection – but unfortunately, they are not perfect. Self-test kits are less accurate than ones that get analyzed in a laboratory, and like any COVID-19 test, they are generally not effective until days after exposure. That means if you contracted COVID-19 at a holiday party on Saturday, a rapid test likely isn’t going to detect anything before Sunday dinner.

Newsletter signup: Get The COVID-19 Brief sent to your inbox

CTVNews.ca reviewed public health guidance from provincial agencies across the country, most of which only advise rapid antigen tests for asymptomatic people. If you take one and test positive, this is what they say you need to do next.

1. Get a laboratory test as soon as possible. These are the kinds of tests that are done at places like hospitals, clinics and pharmacies. Known as polymerase chain reaction (PCR) tests, they are much more accurate than take-home rapid antigen tests.

2. Self-isolate until your lab results come in, even if you don’t have symptoms. If possible, also try to avoid public transportation on your way home from your second test.

3. Tell close contacts and household members, and advise them to self-isolate until your results arrive.

4. If the lab results are positive, your local public health agency will contact you with instructions and next steps, which usually involves at least 10 days of isolation. Household members and close contacts should also get tested.

It’s important to remember that rapid antigen tests are not a substitute for other COVID-19 precautions, such as vaccines, proper masking and hand-washing. Also make sure to only use Health Canada approved kits.

Rapid test availability varies by province and territory, and so do public health policies, which are also subject to change. For more information, see these resources on self-test kits from B.C., Alberta, Saskatchewan, Manitoba, Ontario, Quebec, New Brunswick, P.E.I. and Nova Scotia.

from CTV News - Atlantic https://ift.tt/32acgb0

#new brunswick #prince edward island #nova scotia #news #politics #canada #CTVAtlantic

0 notes

bobwilsonme · 5 years ago

Text

Influenza flu shots to be ready starting Oct. 21 - Weyburn Review

Influenza flu shots to be ready starting Oct. 21 – Weyburn Review

Saskatchewan residents with a valid health card can get their flu shot starting the week of October 21 at public health clinics, local pharmacies, and some physician and Nurse Practitioner offices.

“Although there have been delays in the delivery of this year’s influenza vaccine, the Ministry of Health has confirmed with Health Canada that Saskatchewan will receive vaccine to support the…

View On WordPress

0 notes

pharmacybrandca · 1 year ago

Text

Pharmacy Clinic Saskatchewan Canada

Canada's Fastest-Growing Pharmacy Banner Program

We are committed to providing independent pharmacies the tools, resources, and support to reach their individual success in the communities they serve. 175 banner members and counting! https://www.canva.com/design/DAFnvyFNn2U/dxDItVUQJa5N1uUQiWyhQw/view?utm_content=DAFnvyFNn2U&utm_campaign=designshare&utm_medium=link&utm_source=publishsharelink

#Pharmacy Clinic Saskatchewan Canada

0 notes

covid-safer-hotties · 1 month ago

Text

For Canadians seeking a non-mRNA COVID vaccine, lack of Novavax shot is 'unfair,' advocates say - Published Oct 3, 2024

The federal government's decision to not provide Novavax's COVID-19 vaccine this respiratory virus season raises health equity concerns, experts and advocates say, as some Canadians look to the U.S. to get the shot.

The Public Health Agency of Canada said it won't provide the protein-based vaccine called Nuvaxovid because the manufacturer required a minimum order that far exceeds last year's uptake of the vaccine.

But some Canadians who say they are immunocompromised and have had adverse reactions to the mRNA vaccines are calling the decision unfair.

Wilhelm said the flare-up was so bad that she even had trouble brushing her hair or chopping vegetables.

After searching for Nuvaxovid at various pharmacies and public health clinics, she said she eventually got a dose in April at a

pharmacy in Saint John, N.B., and had no adverse reactions.

"And now, again, I have no options," Wilhelm said, adding that she's considering driving across the border to Maine to get the updated Nuvaxovid shot.

Barry Hunt made the cross-border trip last month from Port Ryerse, Ont., to a pharmacy near Buffalo, N.Y., where he paid US$200 to get the Novavax vaccine.

But he acknowledged that most people seeking Nuvaxovid don't have the means to travel to the U.S. to get it.

"I think it's unfair to people who can't afford it. I think it's ridiculous to both pay taxes here in Canada for universal health care under the Canada Health Act and not be able to access a non-mRNA vaccine," Hunt said.

Angela Rasmussen, a virologist at the University of Saskatchewan's Vaccine and Infectious Disease Organization, said some people may be sensitive to some components of mRNA vaccines but overall they are safe for immunosuppressed people.

"It's disappointing that Novavax won't be available here because I think it could increase vaccine uptake just by virtue of overcoming objections to mRNA vaccines, whether based in truth or not," she said in an email.

Specialists often ask patients with autoimmune diseases to stop taking their medications while they get vaccinated to ensure they can mount a good immune response, and the absence of medication may be what's actually triggering the flare-ups rather than the mRNA vaccine itself, said Dawn Bowdish, an immunology professor at McMaster University in Hamilton.

Still, Nuvaxovid is "clearly less what we call reactogenic, meaning you're less likely to feel poorly or have a sore arm or have any of those side-effects that some people ... get from vaccines," said Bowdish, who has worked with immunocompromised people in clinical studies on mRNA vaccines.

Novavax's vaccine, reformulated to target the recently circulating JN.1 subvariant of Omicron, was authorized by Health Canada in September.

People who have concerns or had a bad immunization experience should have access to Nuvaxovid, Bowdish said, because it's crucial they get some kind of vaccination against COVID-19, which is especially dangerous for the immunocompromised.

The Public Health Agency of Canada said people worried about getting an mRNA vaccine should consult their health-care provider.

Those who are medically unable to receive an mRNA vaccine should protect themselves by practising hand hygiene, wearing a well-fitting mask and improving indoor ventilation, the agency said.

"That response is absolutely appalling," said Michelle Burleigh, co-chair of the Canadian Immunocompromised Advocacy Network, which sent a letter to the federal government in July urging it to procure Novavax.

"It's great if somebody has the financial means and ability to travel to the U.S., but this causes a real health equity issue because there are a lot of Canadians who are not in a position to afford $200 for a vaccine in the United States or have the ability to get there."

Bowdish said she's also aware of people travelling to the U.S. to get Nuvaxovid and that's "really problematic."

Although the latest data suggest flare-ups of certain conditions are unlikely to be a direct result of the mRNA vaccine, it's still important to accommodate patients, she said.

"If a person's personal experience was, `I got vaccinated and I had a flare that put me in bed for two months and ... I missed a part of life,' how on earth do you counter that while being respectful over their autonomy and knowing their own bodies?"

#canada #novavax #covid isn't over #mask up #covid #covid 19 #pandemic #public health #wear a mask #coronavirus #sars cov 2 #wear a respirator #still coviding #covid conscious #covid is airborne #covid19 #covidー19 #covid vaccine

1 note · View note

isupportonlinedoctor · 6 months ago

Text

Book an Appointment with Virtual Doctor Online in Saskatchewan with Gotodoctor.ca The platform integrates virtual care and in-person pharmacy and clinic Service Sites, and enables members to access comprehensive and scalable physician and other healthcare services. Gotodoctor.ca is a preferred provider for McKesson Canada’s Rexall and Retail Banner Group (IDA, Guardian, Remedy’s Rx) pharmacies. Its Digital Employee Services and Data Offerings technologies are already adopted and are utilized by major Canadian Enterprises, TPAs, and other enterprises, like Manitoba Blue Cross, Novartis Canada, SEB Administrative Services, The Leslie Group, Quick Health Access, Simply Bene? Its, and Automated Administration Services.

#online doctor appointment #medical doctor online saskatchewan #virtual doctor #surgical wait times

0 notes

legalseat · 6 years ago

Text

Thirty Years Since Morgentaler

January 28, 2018 marked 30 years since the Supreme Court of Canada struck down Canada’s abortion laws as unconstitutional in R. v. Morgentaler. Since then, the road to legal, accessible, and safe abortion services has been a rocky one. In Manitoba, politicians from across the spectrum have resisted increasing access to abortions since the 1988 constitutional decision.

More recently, discussion surrounding abortion has become one that has focused on access and not of criminalization. Progress in Canada, although slow, has been made. Plan B or colloquially named the “morning after pill” (an emergency contraceptive pill) became available to the public without a prescription in 2005. However, those requesting the pill needed to fill out a form with personal information that remained at the pharmacy. In 2008, this requirement was removed. Similarly, Mifegymiso, aka the abortion pill has also seen a slow introduction into the Canadian health care system, specifically in Manitoba where access has been limited to certain sites. Manitoba and Saskatchewan are the only two provinces that do not provide full coverage for the pill. Under the current guidelines, free access is only available at HSC, Women’s Health Clinic or at the Brandon Regional Health Centre. Access for women outside of these major cities is limited and requires women to pay the full cost which is around $350. Currently, the pill costs around $300, and if you cannot afford that you can only access it at approved sites (in Winnipeg, HSC and Women’s Health Clinic).

The conversation at the political level regarding Mifegmiso seems to be heating up as we also saw a private member’s bill introduced by the NDP that would ban protestors from being with a certain distance from abortion clinics and hospitals in Manitoba. The current government did not support the bill because of the fear that it would infringe on people’s right to protest. Students have also been active in supporting increasing access, where just this week medical students advocated that access to Mifegymiso should be increased.

It seems as though it was a different generation where there it was dangerous to be providing services or advocating on behalf of progress for reproductive rights. Some may not remember an incident that took place in a St. Vital home on November 11, 1997. Dr. Jack Fainman, head of obstetrics and gynecology at Victoria Hospital, was watching TV when he was shot through the back window of his house. He provided abortion services. Although he survived his attack, this was a career ending incident for Dr. Fainman who was not able to practice again. The suspect of the shooting was never conclusively identified, but it has long been assumed that it was American anti-abortionist James Kopp. Kopp’s also shot and killed Dr. Barnett Slepian on October 23, 1998. He is also suspected of shooting two other Canadian doctors. The 1995 attempted murder of Dr. Hugh Short in Ancaster, Ontario and the 1994 shooting of Dr. Garson Romalis in Vancouver, which is considered the first attempted shooting of an abortion provider in Canada. There was also an attempt on an unnamed physician in Rochester, New York in 1997.

Kopp had received his master’s degree in embryology from Cal-State Fullerton and was a well-known anti-abortion advocate. He initially vehemently denied his involvement with Dr. Slepian’s muder however on November 20,2002 in an interview with the Buffalo News he confessed to the murder. He was tried and charged but claimed his intention was never meant to kill Dr. Slepian, simply injure him so that he could not continue providing abortion services. He continues to deny that he had any role in the Canadian shootings.

To be clear, the number of incidents of violence and disruption against abortion providers in Canada and the US has decreased substantially since the 1990’s which saw 8 murders of doctors and clinic staff and 19 attempted murder. Prior to the attack on the Planned Parenthood location in Colorado in 2015 that killed three people, the last attack was in 2009 on Dr. George Tiller, a member of the National Abortion Federation, who was assassinated in his church in Wichita, Kansas. Dr. Tiller was one of few US physicians who performed late term abortion. Dr. Tiller had been shot at once before in 1993 but had survived that attack. The last identified attack in Canada was in 2000 and once again against Dr. Garson Romalis, when he was stabbed in the parking lot of his medical practice. He survived but the suspect was never identified.

It has been 30 years since Morgentaler, and this brief post skims the Canadian history on how we have approached abortion. It seems as though we have come so far from the earlier days of frenzied anti-abortion protests. But have we?

Having spent some time working with an abortion provider in Winnipeg, I recognize clear signs that there remains a dark undercurrent for reproductive access. It is not only featured in the broken window that graces the front of the clinic, or the lack of attention directed at funding, but it is demonstrated in the anonymity of the location where the abortions take place. Just ask yourself, unless you have had to know, do you know where these services are provided? I can tell you it’s an iron orange door. Only accessible with a swipe card, and then you have to be buzzed into as small room, where you will then be granted access the clinic. There is no signage that directs you how to get there and even google requires more than your average search to find information about how to access the clinic. It seems like an oxymoron that as these clinics and advocates attempt to increase accessibility to these services, in order to ensure safety, they actually have to reduce their accessibility by making their locations difficult to find.

Certainly, Canada continues to make progress, and maybe when we celebrate Morgentaler’s 60th anniversary all women can too.

Links and References

http://bit.ly/2vu275m

http://bit.ly/2PCw8ZS

https://nyti.ms/2oHhB3f

http://bit.ly/2PCVib1

http://bit.ly/2vydoSe

http://bit.ly/2PF4tHO

http://bit.ly/1iuQHFV

http://bit.ly/2PH0LgN

https://nyti.ms/2oHhB3f

Thirty Years Since Morgentaler published first on https://divorcelawyermumbai.tumblr.com/

0 notes

atlanticcanada · 7 years ago

Text

Big pharma snub, placebo snag to blame for lack of medical pot research: experts

VANCOUVER -- A disinterested pharmaceutical industry and the conundrum of finding a convincing placebo are just two reasons experts say there has been little quality research into medicinal marijuana.

A growing number of Canadians are turning to medical cannabis despite questions about its risks and effectiveness as a health product.

Marijuana's unconventional journey onto the medical market puts it at odds with more mainstream medications, which typically undergo years of costly scrutiny before being approved for use, said Mark Ware, a pain researcher at McGill University Health Centre in Montreal.

Ware said pharmaceutical companies are willing to pay hundreds of millions of dollars for clinical trials because once a drug is approved they have a window of time to sell it exclusively.

"When you think about medications that have been given approval to be sold in pharmacies, that's where most if not all of our medications come from," he said.

"That model simply does not hold for much of the classical herbal cannabis research, where you're looking for basic claims of efficacy and safety, but not trying to make a formal claim for a product that is going to be patented."

Ware, who also served as vice-chair on the federal government's task force on legalizing cannabis, said competition among licensed marijuana producers is leading some of them to funnel money toward research in an effort to differentiate their brand from others.

But Dr. Mike Allan, a professor of family medicine at the University of Alberta in Edmonton, said there are few benefits for producers to conduct the research.

"It's already at market so there's really no incentive, or virtually no incentive, for licensed producers to take the money they're generating from the sale of these products and reinvest it in research," Allan said.

While a positive outcome might not have much of an effect on the industry's bottom line, a negative outcome could seriously harm profits, he added.

Data from Health Canada show the number of clients registered with licensed medicinal cannabis producers jumped between June 2016 and June 2017, from 75,166 to more than 200,000. Registrations more than tripled in each of the two previous years.

University of Saskatchewan professor, Robert Laprairie, said the absence of the pharmaceutical industry means medical marijuana research is being done for the benefit of the patient.

"We're in a unique place because a lot of large pharmaceutical companies are reluctant to fund these studies where they don't necessarily see the incentive for something that they aren't able to patent," said Laprairie, who conducts cannabinoid research at the university.

Laprairie said he has seen a heavy push in recent months from academics, patients and licensed producers for more medical cannabis research.

But Dr. Meldon Kahan of the Women's College Hospital in Toronto, said this kind of research, sponsored by licensed producers, is still problematic.

"You can design a short-term study with marijuana, or for that matter, with alcohol or opiates, and say, 'Look, we gave people a bunch of alcohol over a three-day period or one week or one month and they seem to feel better. It helped their anxiety.' But that doesn't mean it's a good medication," he said.

Kahan said there does appear to be some evidence that cannabidiol, a compound in marijuana, does have some medical benefits, including pain relief, but more study is needed.

Ware said another dilemma in conducting research on medical marijuana is the absence of a plausible placebo, especially because study participants often have experience using cannabis and recognize if they have been placed in the study or control group.

"Access to a credible placebo may seem like an odd thing to have as a challenge," Ware said.

"But bear in mind that many of these studies are placebo-controlled, so you need a drug which is a credible placebo -- looks and smells and for all intents and purposes pretends it is cannabis when in fact it does not have the active ingredient you are testing."

from CTV News - Atlantic http://ift.tt/2C8KHQz

#new brunswick #prince edward island #nova scotia #news #politics #canada #CTVAtlantic

0 notes

legalroll · 6 years ago

Text

Thirty Years Since Morgentaler

Certainly, Canada continues to make progress, and maybe when we celebrate Morgentaler’s 60th anniversary all women can too.

Links and References

http://bit.ly/2vu275m

http://bit.ly/2PCw8ZS

https://nyti.ms/2oHhB3f

http://bit.ly/2PCVib1

http://bit.ly/2vydoSe

http://bit.ly/2PF4tHO

http://bit.ly/1iuQHFV

http://bit.ly/2PH0LgN

https://nyti.ms/2oHhB3f

Thirty Years Since Morgentaler published first on https://medium.com/@SanAntonioAttorney

0 notes

abigailswager · 6 years ago

Text

Aleafia Health Inc. to Acquire Emblem Corp. to Create New Medical Cannabis Leader

New Post has been published on https://cfddesk.net/aleafia-health-inc-to-acquire-emblem-corp-to-create-new-medical-cannabis-leader/

Aleafia Health Inc. to Acquire Emblem Corp. to Create New Medical Cannabis Leader

Combination will create Canada’s largest medical cannabis clinic network with access to 40 medical clinics and education centres;

Aleafia patients to access Emblem’s differentiated, high margin derivative products including capsules, oils and oral sprays, along with award-winning customer service and eCommerce platform;

Regulatory acceleration with Aleafia leveraging Emblem’s Health Canada License to extract and process medical cannabis products and sell them directly to patients;

Aleafia to become among national leaders in production capacity (including committed supply agreements);

Expansion of Aleafia’s national and global distribution platform;

Increased scale of the combined company will enhance its capital markets profile and increase trading liquidity; and

Combination results in current cash resources of approximately $70 million.

TORONTO, December 19, 2018 – Aleafia Health Inc. (TSXV: ALEF) (“Aleafia” or the “Company“) and Emblem Corp. (TSXV: EMC, OTCQX: EMMBF) (“Emblem“) are pleased to announce that they have entered into a definitive agreement (the “Agreement“) under which Aleafia will acquire, by way of a plan of arrangement under the Canada Business Corporations Act, all of Emblem’s issued and outstanding common shares in an all-share transaction currently valued at approximately $173.2 Million (the “Transaction“).

The Agreement calls for Emblem shareholders to receive 0.8377 of an Aleafia common share (each whole share, an “Aleafia Share“) in exchange for each Emblem common share (each, an “Emblem Share“), representing the equivalent of $1.21 per Emblem Share and a premium of 27.0% based on the closing prices of Aleafia and Emblem Shares on the TSX Venture Exchange (“TSXV“) on December 18, 2018. When the Transaction is completed, it is expected that existing Aleafia and Emblem shareholders will own approximately 59.0% and 41.0% of Aleafia, respectively, on a fully diluted in-the-money basis. The Transaction has been unanimously approved by Emblem’s Special Committee and Board of Directors.

Transaction Highlights

The proposed Transaction creates a new Canadian medical cannabis leader. It will operate the country’s largest national clinic network and enjoy improved operational scale with planned annual capacity of approximately 138,000 kg (including committed supply agreements), Canadian and expanded global distribution, and a robust branding and product development platform. Aleafia intends to capitalize on high growth opportunities and leverage international expansion across four verticals: Cannabis Production, Health and Wellness, Cannabis Education and the Consumer Experience.

The Leading Canadian Clinic Network: Combining Canabo Medical Clinic and GrowWise Health creates the leading Canadian clinic network with access to 40 national medical clinics and education centres that have served almost 60,000 patients, with increases in patient visits and referrals since October 17, 2018. In addition, Aleafia will be able to leverage Emblem’s extraction, and product innovation to, for the first time, sell high-margin medical cannabis directly to Aleafia’s patient base.

High-Margin, Highly Differentiated Medical Product Portfolio: Aleafia’s patient base will enjoy access to Emblem’s differentiated, high margin derivative products including capsules, oils and oral sprays, with industry leading recognized revenue per gram rates. Patients will also access Emblem’s award-winning customer service, scheduled home delivery and eCommerce platform.

Scaled Production Capacity and Leading Supply: Aleafia will be a leading licensed producer of cannabis with approximately 138,000 kg of production and supply across three Ontario facilities and the industry’s largest LP to LP cannabis supply agreement.

National and Global Distribution Platform: Aleafia expects to leverage Emblem’s approval to supply to the Provinces of Ontario, Saskatchewan, British Columbia and Alberta; national medical distribution through Shoppers Drug Mart; and national retail distribution through Fire & Flower, Starbuds and the emerging OnePlant network. In addition, through Emblem’s joint venture with German pharmaceutical wholesaler Acnos Pharma GmbH, Aleafia expects to access the world’s largest medical cannabis market serving more than 82 million people, with access to approximately 20,000 pharmacies, along with access to Australia’s burgeoning medical cannabis market upon completion of Aleafia’s previously announced transaction with CannaPacific Pty Ltd.

Industry Leading Adult-use Brands: Complementing Aleafia’s adult-use strategy via the transactions with Serruya Private Equity, Aleafia will leverage Emblem’s flagship brand Symbl, which is ranked one of the top selling recreational brands.

Focus on Product Development: Aleafia will build on Emblem’s product development success. Based out of Emblem’s state-of-the-art Product Innovation Centre, product development will focus on potential innovations in high-margin, branded beverages, edibles, vape pens, topicals and concentrates for the medical and adult-use markets.

Improved Capital Markets Profile: Aleafia will be a leading licensed producer appealing to a broader shareholder base, with greater access to capital and improved trading liquidity.

Robust Cash Position: Aleafia and Emblem currently have access to a combined CAD $69.9 million in cash, to be used for continued product innovation and brand building, construction and development of their cultivation facilities and outdoor grow operations, to support expansion efforts and to pursue strategic opportunities and investments that maximize shareholder value.

“The Emblem acquisition rapidly accelerates the execution of Aleafia’s strategy to become a vertically integrated, diversified cannabis company. It is difficult to overstate the significance of securing the highest quality medicine for our patients and Aleafia” said Aleafia Health CEO Geoffrey Benic. “Emblem’s product leadership in the medical and adult-use sectors and highly coveted supply agreements will perfectly complement Aleafia’s cannabis production and clinic operations. This is a transformative transaction that positions Aleafia as a global cannabis leader.”

“Emblem’s patient-focused product portfolio and strength in patient education, conversion and retention through GrowWise will be further bolstered by the patient acquisition capabilities of Aleafia’s Canabo clinics. The combination of the companies will form a fully integrated market leader in the medical cannabis sector, with industry leading patient counts, and the ability to immediately capitalize on full revenue potential,” said Emblem CEO Nick Dean. “Furthermore, our renowned national brands, robust footprint in emerging value-added products, and strong domestic and international growth opportunities, will cement our position of strength in this highly competitive market.”

Additional Transaction Details

The Transaction will be effected by way of a court-approved plan of arrangement completed under the Canada Business Corporations Act and will require approval by at least 66 2/3% of the votes cast by the shareholders of Emblem present in person or by proxy at a special meeting of Emblem shareholders.

Upon completion of the Transaction, two (2) independent directors of Emblem will be appointed to serve on the board of directors of Aleafia, being Daniel Milliard and Loreto Grimaldi who will replace two (2) directors of Aleafia.

The Agreement includes customary provisions including reciprocal non-solicitation provisions, subject to the right of each of Emblem and Aleafia to accept a superior proposal/competing transaction in certain circumstances, with both Emblem and Aleafia having a seven (7) business day right to match any such superior proposal/competing transaction for the other party. The Agreement also provides for reciprocal termination fees of $10 million if the Transaction is terminated in certain specified circumstances.

In addition to shareholder approvals, the Transaction is subject to the receipt of certain regulatory, court and stock exchange approvals, the obtaining of material consents / waivers and the satisfaction of other conditions customary in transactions of this nature.

Aleafia has entered into support and voting agreements with each of Emblem’s directors, Emblem’s CEO and CFO, along with additional shareholders who have agreed to support and vote for the Transaction and who represent in aggregate approximately 11.8% of the outstanding Emblem shares.

It is expected that holders of Emblem options will receive replacement Aleafia options (on the same terms as the Emblem options), and holders of Emblem warrants will receive, upon exercise, the same consideration they would have received as if they were Emblem shareholders at the closing of the Transaction.

Aleafia and Emblem have also entered into an agreement with a holder representing 69.44% of the principal amount of Emblem’s convertible debentures pursuant to which such holder has agreed not to accept any change of control offer to the extent one is made, and the parties have agreed to use their commercially reasonable efforts to amend the trust indenture to amend the change of control provisions such that they do not apply to the Transaction, and to reduce the conversion price from $2.30 to $2.00.

Further information regarding the Transaction will be included in the information circular that Emblem will prepare, file, and mail in due course to its shareholders in connection with its special meeting to be held to consider the Transaction which is expected to occur before March 8, 2019. The Agreement will be filed on the SEDAR profiles of Emblem and Aleafia on the SEDAR website at www.sedar.com.

Emblem Board of Director’s Recommendations

The board of directors of Emblem (the “Emblem Board“) has unanimously determined, after receiving the unanimous recommendation of its Special Committee and financial and legal advice, that the consideration to be received by the Emblem shareholders is fair from a financial point of view and that the Arrangement is in the best interests of Emblem and its security holders, and the Emblem Board unanimously recommends that the Emblem shareholders vote in favour of the Transaction.

The Emblem Board and its Special Committee have each obtained a fairness opinion from Eight Capital and Echelon Wealth Partners Inc., respectively, that, as of the date of the opinions, and subject to the assumptions, limitations, and qualifications on which such opinions are based, the consideration to be received by Emblem shareholders pursuant to the Agreement is fair, from a financial point of view, to the Emblem shareholders.

Legal and Financial Advisors

Gowling WLG (Canada) LLP is acting as legal counsel to Aleafia. Deloitte advised Aleafia on financial due diligence. Mackie Research Capital Corporation is acting as financial advisor to Aleafia. In addition to other fees and expenses payable to Mackie, Aleafia is required to pay a success fee (the “Success Fee“) to Mackie upon closing of the Transaction equal to 2.0% of the aggregate fair market value of the share consideration issuable by Aleafia to Emblem’s shareholders and the amount of net debt of Emblem (as of its most recent balance sheet prior to the closing of the Transaction, and calculated as the sum of the long term debt and debentures) which is assumed or acquired by Aleafia, or retired or otherwise extinguished in connection with the Transaction (expected to be $30.5 million). The Success Fee is payable in common shares of Aleafia subject to acceptance of the TSX Venture Exchange.

Dentons Canada LLP is acting as legal counsel to Emblem. Eight Capital is acting as financial advisor to Emblem and Echelon Wealth Partners Inc. is acting as financial advisor to the Special Committee. Eight Capital and Echelon Wealth Partners Inc. have each provided a fairness opinion to the Emblem Board and the Special Committee, respectively.

Conference Call and Slide Presentation

Aleafia and Emblem will hold a webcast conference call, including a slide presentation, to discuss the Transaction.

Date: Wednesday December 19, 2018

Time: 8:30am (Toronto Time)

USA/Canada Toll-Free Participant Call-in: (866) 679-9046; Passcode: 9579635

International Toll-Free Participant Call-in: (409) 217-8323; Passcode: 9579635

Webcast Link: https://edge.media-server.com/m6/p/4pcbtcdd

This conference call will be webcast live over the internet and can be accessed through the link provided. Audio of the call will be available to participants through both the conference call line and webcast, however questions to management may only be submitted via the webcast.

For Additional Information and Support:

Aleafia Health Inc.

Nicholas Bergamini VP Public Affairs, Aleafia Health Inc. 416-860-5665 [email protected]

Emblem Corp.

Morgan Cates H+K Strategies 416-413-4649 [email protected]

Alex Stojanovic Chief Financial Officer, Emblem Corp. 647-748-9696 [email protected]

About Aleafia Health Inc.

Aleafia is a leading, vertically integrated cannabis company with major cannabis cultivation & processing and medical cannabis clinics business operations. Aleafia owns two cannabis cultivation facilities, one of which is licensed and fully operational and one which will be fully operational in early 2019. Aleafia will reach a fully-funded annual growing capacity of 98,000 kg in 2019. Canabo Medical Clinics are the largest brick and mortar medical cannabis clinic network in Canada with 22 locations and over 50,000 patients.

About Emblem Corp.

Emblem is a fully integrated cannabis company focused on driving shareholder value through product innovation, brand relevance, and access to patient and consumer channels. Through its wholly-owned subsidiary Emblem Cannabis Corporation, Emblem is licensed to cultivate, process, and sell cannabis and cannabis derivatives in Canada under the Cannabis Act. Emblem’s state-of-the-art indoor cannabis cultivation facility and Product Innovation Centre is located in Paris, Ontario. Emblem is also the parent company of GrowWise Health Limited, one of Canada’s leading cannabis education services. Emblem trades under the ticker symbol EMC on the TSX Venture Exchange.

For more information, please visit www.emblemcorp.com.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Note Regarding Forward-Looking Statements:

Certain information in this news release constitutes forward-looking statements under applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward looking statements are often identified by terms such as “may”, “should”, “anticipate”, “expect”, “potential”, “believe”, “intend” or the negative of these terms and similar expressions. Forward-looking statements in this news release include, but are not limited to, statements with respect to accretive earnings, anticipated revenue and costs synergies associated with the acquisition of Emblem, statements with respect to internal expectations, estimated margins, expectations for future growing capacity, costs and opportunities, the effect of the transaction on the combined company and its strategy going forward, expectations for receipt of licenses to cultivate, process or distribute medical cannabis in Federally legal markets, the completion of any capital project or expansions, the expectations with respect to future production costs, the anticipated timing for the special meeting of Emblem shareholders and closing of the Transaction; the consideration to be received by shareholders, which may fluctuate in value due to Aleafia common shares forming the consideration; the satisfaction of closing conditions including, without limitation (i) required Emblem shareholder approval; (ii) necessary court approval in connection with the plan of arrangement, (iii) Aleafia obtaining the necessary approvals from the TSX Venture Exchange for the listing of securities in connection with the Transaction; and (iv) other closing conditions, including, without limitation, obtaining certain consents, the operation and performance of the Emblem and Aleafia businesses in the ordinary course until closing of the Transaction and compliance by Emblem and Aleafia with various covenants contained in the Agreement. In particular, there can be no assurance that the Transaction will be completed. Forward looking statements are based on certain assumptions regarding Emblem and Aleafia, including expected growth, results of operations, performance, industry trends and growth opportunities. While Emblem and Aleafia consider these assumptions to be reasonable, based on information currently available, they may prove to be incorrect. Readers are cautioned not to place undue reliance on forward-looking statements. Forward-looking statements also necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; marketing costs; loss of markets; future legislative and regulatory developments involving the medical and adult-use marijuana markets; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; the medical and adult-use marijuana industries generally; income tax and regulatory matters; the ability of Aleafia and Emblem to implement their business strategies; competition; crop failure/conditions; currency and interest rate fluctuations and other risks.

Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.

Forward-looking statements contained in this news release are expressly qualified by this cautionary statement and reflect our expectations as of the date hereof, and thus are subject to change thereafter. Emblem and Aleafia disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. This news release has been approved by the Board of Directors of each of Aleafia and Emblem. Factors that could cause anticipated opportunities and actual results to differ materially include, but are not limited to, matters referred to above and elsewhere in Emblem’s and Aleafia’s public filings and material change reports that will be filed in respect of this Transaction which are and will be available on SEDAR.

#emblemcorp.com

0 notes

rickcheetham · 7 years ago

Photo

Traveling with medicine

Before escaping from this cold weather and going on that hot holiday you are excited to take be sure to plan ahead when traveling with your medication. Not all legal prescription medications in Canada are considered legal in the foreign country you are visiting and the best way to find out is to contact the foreign government offices in Canada. Here are some tips to save you time at the airport:

Pack all medications in your carry-on bag in their original, labelled containers. Prescription medication is exempted from the liquid restriction but still must be presented to screening officer separately from carry-on baggage Do not try to save luggage space by combing medications into a single container. Always pack more medication than anticipated days away in case you are delayed longer than expected. Carry a copy of the original prescription to ensure both the generic and trade names are included in case of theft or loss. Also, a doctor’s note describing why you are taking the medication is also recommended. The limit of two carry-on bags does not apply to medical supplies, equipment and mobility aids. If travelling with needles or syringes carry an explanation from your health care provider. Needles and syringes may be difficult to purchase abroad so carry enough for the entire trip.

There are also some things to avoid while traveling as other countries hold certain risks. To limit those risks here are some things you should do:

Pack a travel health kit that can include things such as acetaminophen (Tylenol) or ibuprofen (Advil) for pain and fever, decongestant alone or in combo with an antihistamine in case you get sick while traveling, cough candies, loperamide (Imodium) for diarrhea, Benadryl for allergies to new environments, Band Aids, hydrocortisone cream for red itchy rashes from plants or bug bites, dimenhydrinate (Gravol) for motion sickness, antibacterial (Polysporin) and antifungal ointment, antacids, mild laxative, lubricating eye drops, and oral rehydration packs. I know this list seems extensive, but I live by the moto be prepared!

Make sure to pack sunscreen, aloe gel for sun burns, and insect repellent. It is also great to have antibacterial wipes or hand sanitizer, and tweezers for slivers. Avoid injections while traveling unless it’s an emergency. Get vaccinated against Hepatitis A and B and be sure to check for other vaccines that may be required by discussing your travel plans with a health care provider or visit a travel health clinic at least 6 weeks before, preferably.

You may require antimalarial medication to take with you

Finally here are some general tips to follow before leaving:

Buy extra travel insurance and always carry proof of your health insurance coverage, even short hospital stays in most countries are in the thousands and is not covered by your Saskatchewan Health coverage. It is always a good idea to make copies of your passport and travel documents and put in each piece of luggage and one to give to a family member or friend.

All information for this article was provided by travel.gc.ca and cdc.gov.

Sources

https://wwwnc.cdc.gov/travel/page/pack-smart#travelhealthkit Traveler’s Health Pack Smart

https://travel.gc.ca/travelling/health-safety/medication Travelling with medication

Cheetham’s Pharmacy 514 Queen St Saskatoon, SK, S7K 0M5 306-653-5111, 306-653-1661 fax, toll free 1-800-695-4788

Visit us online at www.cheethamspharmacy.ca , your Trusted Saskatoon Pharmacy.

#saskatoon #wellness #seniors #yxe #pharmacy #healthyliving #trustedsaskatoon #FluShot #Flu #Colds #prevention #Medicine #CheethamsPharmacy #5Rs #Canada150

0 notes

asktheexpertsco-blog · 8 years ago

Text

Saskatoon Seniors Wellness &Pharmacy - LaVerne Churko

http://theexperts.ca/blog/2017/02/13/saskatoon-seniors-wellness-pharmacy-laverne-churko-2/

Traveling with medicine

Pack all medications in your carry-on bag in their original, labelled containers.

Prescription medication is exempted from the liquid restriction but still must be presented to screening officer separately from carry-on baggage

Do not try to save luggage space by combing medications into a single container.

Always pack more medication than anticipated days away in case you are delayed longer than expected.

Carry a copy of the original prescription to ensure both the generic and trade names are included in case of theft or loss. Also, a doctor's note describing why you are taking the medication is also recommended.

The limit of two carry-on bags does not apply to medical supplies, equipment and mobility aids.

If travelling with needles or syringes carry an explanation from your health care provider. Needles and syringes may be difficult to purchase abroad so carry enough for the entire trip.

There are also some things to avoid while traveling as other countries hold certain risks. To limit those risks here are some things you should do:

Make sure to pack sunscreen, aloe gel for sun burns, and insect repellent.

It is also great to have antibacterial wipes or hand sanitizer, and tweezers for slivers.

Avoid injections while traveling unless it's an emergency.

Get vaccinated against Hepatitis A and B and be sure to check for other vaccines that may be required by discussing your travel plans with a health care provider or visit a travel health clinic at least 6 weeks before, preferably.

You may require antimalarial medication to take with you

Finally here are some general tips to follow before leaving:

It is always a good idea to make copies of your passport and travel documents and put in each piece of luggage and one to give to a family member or friend.

All information for this article was provided by travel.gc.ca and cdc.gov.

Sources

https://wwwnc.cdc.gov/travel/page/pack-smart#travelhealthkit Traveler's Health Pack Smart

https://travel.gc.ca/travelling/health-safety/medication Travelling with medication

1-800-695-4788, www.cheethamspharmacy.ca.